ID   ARCaP
AC   CVCL_4830
SY   MDA-PCa-1; MDA-Pca-1; MDA PCa 1; M.D. Anderson-Prostate Cancer-1
DR   cancercelllines; CVCL_4830
DR   IARC_TP53; 18890
DR   TOKU-E; 4101
DR   Wikidata; Q54750438
RX   CelloPub=CLPUB00698;
RX   PubMed=8986779;
RX   PubMed=12725112;
RX   PubMed=14518029;
RX   PubMed=14518030;
RX   PubMed=15643172;
WW   https://web.archive.org/web/20160703200724/http://capcelllines.ca:80/details.asp?id=85
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=14518029).
CC   Caution: While some papers (PubMed=14518029; PubMed=14518030) believe that ARCaP and MDA-PCa-1 are two separate cell lines originating from the same patient, the current view is that ARCaP was renamed MDA-PCa-1 when further prostate cancer cell lines (MDA-PCa-2a/2b) were established at MD Anderson.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=14518029
ST   Amelogenin: X,Y
ST   D13S317: 11
ST   D18S51: 15
ST   D21S11: 29
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   D8S1179: 10,12
ST   FGA: 21
ST   vWA: 18,19
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   83Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands.
//
RX   PubMed=8986779; DOI=10.1073/pnas.93.26.15152; PMCID=PMC26372;
RA   Zhau H.-Y.E., Chang S.-M., Chen B.-Q., Wang Y.-L., Zhang H.-Q.,
RA   Kao C.-H., Sang Q.-X.A., Pathak S., Chung L.W.K.;
RT   "Androgen-repressed phenotype in human prostate cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:15152-15157(1996).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=14518030; DOI=10.1002/pros.10291;
RA   van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S.,
RA   Nordeen S.K., Miller G.J., Varella-Garcia M.;
RT   "Spectral karyotype (SKY) analysis of human prostate carcinoma cell
RT   lines.";
RL   Prostate 57:226-244(2003).
//
RX   PubMed=15643172; DOI=10.1097/01.ju.0000141580.30910.57;
RA   Sobel R.E., Sadar M.D.;
RT   "Cell lines used in prostate cancer research: a compendium of old and
RT   new lines -- part 1.";
RL   J. Urol. 173:342-359(2005).
//